跳至主要内容
临床试验/EUCTR2015-005234-21-NL
EUCTR2015-005234-21-NL进行中(未招募)1 期

A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache

Eli Lilly and Company0 个研究点目标入组 324 人开始时间: 2017年3月14日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
324

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Participants who participated in and completed either Study CGAL or Study CGAM.
  • •Investigator judges the participant as reliable to follow all study procedures, keep all study visits, and be compliant with study requirements.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 304
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 20

排除标准

  • •Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device (with the exception of Study CGAL or Study CGAM).
  • •Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF) (with the exception of Study CGAL or Study CGAM).
  • •A history of migraine variants that could implicate or could be confused with ischemia.
  • •Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins.
  • •A history or presence of other medical illness that indicates a medical problem that would preclude study participation.
  • •Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator.
  • •Women who are pregnant or nursing.

研究者

相似试验